ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Gyo Sagara Code No: 4528 at the first section of the Tokyo and Osaka Stock Exchange INQUIRIES: Kinya Morimoto, Managing Director, Corporate Communications

Announcement on Results and Completion of Acquisition of the Company's Own Shares

Pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Corporate Law of Japan

Ono Pharmaceutical Co., Ltd. announced today that it completed an acquisition of its own shares pursuant to Article 156 of the Corporate Law of Japan which is applicable in accordance with Article 165, paragraph 3 of the same as follows. The acquisition program had been resolved at the meeting of its Board of Directors held on November 4, 2010.

The Results

(1) Class	of shares acquired	Common stock of the company	
(2) Total	number of shares acquired	771,400 shares	
(3) Aggr	egate amount of acquisition cost	JPY 3,198,148,000	
(4) Perio	d of acquisition	From To	February 24, 2011 March 24, 2011
(5) Meth	od of acquisition	Purchased on the Osaka Stock Exchange	

(Reference)

1. Resolution at the meeting of its Board of Directors held on November 4, 2010.

(1)	Class of shares to be acquired	Common stock of the company
(2)	Total number of shares to be acquired (equivalent to 7.82% of a total number of the company's	8,500,000 shares (maximum) shares issued excluding retained own shares)
(3)	Aggregate amount of acquisition cost	JPY 30 billion (maximum)

(4) Period of acquisition (contract basis)	From	November 5, 2010
	То	March 24, 2011

2. Accumulated company's own shares acquired based on the above resolution

(1)	Total number of shares acquired	2,709,900 shares
(2)	Aggregate amount of acquisition cost	JPY 10,767,323,996